Publication

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis

Authored by:

Chen C, Liceras FC, Flasche S et al.

Full Citation:

Chen C, Liceras FC, Flasche S et al. 2019. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Global Health. 7(1).

View Publication

Additional key concepts from this publication:

Vaccines are most cost-effective in low-income groups and regions.

Key Evidence: In an analysis of the impact and cost-effectiveness of pneumococcal conjugate vaccines (PCV) in preventing disease and deaths in children under five years in 180 countries, the vaccination was most cost-effective in low income regions and Gavi-eligible countries. The average cost per disability adjusted life year (DALY) was $118 in Africa, $853 in Asia, and $16,000 in Europe. PCV introduction throughout Africa would account for nearly 70% of lives saved globally, but requires only 12% of the global investment.

From the VoICE Editors: The cost estimates were calculated in international dollars.

Use of vaccines, including strengthening existing immunization programs, provides opportunities for significant reductions in disease burden with resultant economic benefits.

Key Evidence: Vaccination of infants with pneumococcal conjugate vaccines in 180, from the health system perspective, would save an estimated $3.2 billion per year worldwide in treatment costs and an additional $2.6 billion in societal costs (from reduced missed work and out-of-pocket expenditures)- for a total of $5.8 billion. These savings would partially offset the estimated global cost of vaccination of $15.5 billion per year.

From the VoICE Editors: The cost estimates were calculated in international dollars.